Literature DB >> 29451142

Cost Analysis of Cervical Cancer Patients with Different Medical Payment Modes Based on Gamma Model within a Grade A Tertiary Hospital.

Suo-Wei Wu1, Tong Chen1, Qi Pan1, Liang-Yu Wei1, Qin Wang1, Jing-Chen Song1, Chao Li1, Ji Luo1.   

Abstract

BACKGROUND: Cervical cancer shows a growing incidence and medical cost in recent years that has increased severe financial pressure on patients and medical insurance institutions. This study aimed to investigate the medical economic characteristics of cervical cancer patients with different payment modes within a Grade A tertiary hospital to provide evidence and suggestions for inpatient cost control and to verify the application of Gamma model in medical cost analysis.
METHODS: The basic and cost information of cervical cancer cases within a Grade A tertiary hospital in the year 2011-2016 were collected. The Gamma model was adopted to analyze the differences in each cost item between medical insured patient and uninsured patients. Meanwhile, the marginal means of different cost items were calculated to estimate the influence of payment modes toward different medical cost items among cervical cancer patients in the study.
RESULTS: : A total of 1321 inpatients with cervical cancer between the 2011 and 2016 were collected through the medical records system. Of the 1321 cases, 65.9% accounted for medical insured patients and 34.1% were uninsured patients. The total inpatient medical expenditure of insured patients was RMB 29,509.1 Yuan and uninsured patients was RMB 22,114.3 Yuan, respectively. Payment modes, therapeutic options as well as the recurrence and metastasis of tumor toward the inpatient medical expenditures between the two groups were statistically significant. To the specifics, drug costs accounted for 37.7% and 33.8% of the total, surgery costs accounted for 21.5% and 25.5%, treatment costs accounted for 18.7% and 16.4%, whereas the costs of imaging and laboratory examinations accounted for 16.4% and 15.2% for the insured patient and uninsured patients, respectively. As the effects of covariates were controlled, the total hospitalization costs, drug costs, treatment costs as well as imaging and laboratory examination costs showed statistical significance. The total hospitalization costs, drug costs, treatment costs as well as imaging and laboratory examination costs of insured patient were 1.33, 1.42, 1.52, and 1.44 times of uninsured patients.
CONCLUSIONS: The analysis of different payment modes toward the medical economic characteristics based on Gamma model is basically rational. Medical payment modes are having certain influence toward the hospitalization expenses of cervical cancer patients in an extent, as drug costs, treatment costs, and examination costs appear to be the main causes.

Entities:  

Keywords:  Cervical Cancer; Cost Analysis; Medical Insurance; Medical Management

Mesh:

Year:  2018        PMID: 29451142      PMCID: PMC5830822          DOI: 10.4103/0366-6999.225052

Source DB:  PubMed          Journal:  Chin Med J (Engl)        ISSN: 0366-6999            Impact factor:   2.628


INTRODUCTION

As one of the most commonly seen gynecologic malignant tumors, cervical cancer is showing a growing tendency of incidence and medical cost in recent years.[1] The treatment of cervical cancer is mainly based on surgeries combined with radiotherapy and chemotherapy that usually takes a long period of time, and the costs of therapies are growing year on year. As one of the medical insurance coverage disease types, its long therapeutic cycle and high treatment costs are bringing severe financial pressures to the patients and medical insurance institutions that have gradually arouse the attention of health administrative departments. The reasonable cost control of inpatient medical expenditures for cervical cancer is crucial in easing the economic burden of patients and medical insurance reimbursements.[2] Extensive studies showed that among varied factors that affect the hospitalization expenses, payment modes can be counted as one of the most important aspects since medical insurances may compensate a great proportion of medical costs that are likely to increase the possibility of overtreatment despite the fact in reducing the financial burden of patients.[3] As a type of sophisticated statistical model, gamma distribution has been widely applied in cost analysis in recent years due to its universal characteristics in the research of health economics.[4] It is believed that logarithmic linked Gamma model is more suitable for cost analysis since the estimated values are closer to the actual value in compare with multiple linear regression method according to relevant researches. In view of the skewed distribution of the cost, the Gamma model is able to process the data with log linked gamma distribution to ensure the integrity of original information and avoid conversion bias.[5] However, extensive studies of medical cost analysis using Gamma model are still rare. This paper chose the inpatient cervical cancer cases within a Grade A tertiary hospital of the year 2011–2016 as research samples to verify the application of Gamma model in medical cost analyses. Furthermore, it is hoped that the study of different medical payment modes toward hospitalization expenses can provide solid basis and rational suggestions of cost control for hospitals as well as health administrative and medical insurance departments.

METHODS

Acquisition and reduction of data and materials

The data and information of patients whose main diagnoses are labeled as cervical cancer from January 1, 2011, to December 31, 2016, within a Grade A tertiary hospital of Beijing were collected through the medical record management system. The data and materials collected included the general situation of the patients (such as age, gender, operations, payment modes, length of hospital stays, admission conditions, treatments, and follow-up situations) and medical costs information including total costs, bed charges, drug costs, treatment costs, examination costs, and other costs.[6] In regards of eliminating the impact of price fluctuation toward the study to realize the comparability of time span,[7] the costs of hospitalization were adjusted according to consumer price index in the “China statistical yearbook – Category of health” of the year 2011–2016, with 2016 as the base year [Table 1].
Table 1

Adjustment of medical cost according to CPI of 2011–2016

YearsCPIMedical costs before the adjustmentMedical costs after the adjustment
20161.020Y1Y1’ = Y1
20151.013Y2Y2’ = Y2 × 1.020
20141.013Y3Y3’ = Y3 × 1.020 × 1.013
20131.020Y4Y4’ = Y4 × 1.020 × 1.013 × 1.013
20121.034Y5Y5’ = Y5 × 1.020 × 1.013 × 1.013 × 1.020
20111.032Y6Y6’ = Y6 × 1.020 × 1.013 × 1.013 × 1.020 × 1.034

CPI: Consumer price index.

Adjustment of medical cost according to CPI of 2011–2016 CPI: Consumer price index.

Statistical analysis

The basic information of patients was examined through Kolmogorov-Smirnov normality test.[8] Since age, length of hospital stay, and medical costs were not subject to normal distribution, median numbers were adopted in the description, while percentages were adopted to indicate the constitution of each cost item toward the total, and a relative number was used in describing categorical variables.[9] Meanwhile, Chi-square test was used to analyze the difference between the basic information of medical insured and uninsured patients. Setting each medical cost item as dependent variables and set age, marriage status, payment modes, therapeutic options, surgical treatments, pathological type, lymphatic metastasis, as well as distant metastasis and recurrence of the patients as independent variables to construct the logarithmic linked Gamma model.[10] Analyze the variance of inpatient medical expenditures of patients with and without medical insurance as well as the influencing factors of hospitalization expenses. Meanwhile, marginal costs of medical insured patients and uninsured patients were estimated in the study.[11] All the data and material collected were entered into Excel 2010 software for Microsoft (Microsoft Corporation, Washington, USA), and statistical analyses were performed using SPSS software version 21.0 (SPSS Inc., Chicago, IL, USA).

RESULTS

General situations

A total of 1321 cases of cervical cancer were enrolled in this study, among which 65.9% were medical insured patients and 34.1% were uninsured patients. The median length of hospital stay was 10.5 days and the median age of the enrolled cases was 49.3 years, and 79.9% of patients were performed with surgeries. The general situations of medical insured patients and uninsured patients were shown in Table 2, in which the marital status and treatment options were statistically significant, while other factors showed no significant difference between the two groups.
Table 2

Basic information of medical insured and uninsured patients (n (%))

VariablesInsured patients (n = 871)Uninsured patients (n = 450)χ2P
Age
 ≤20 years25 (2.8)16 (3.6)4.0020.258
 21–30 years51 (5.8)35 (7.7)
 31–40 years121 (13.9)68 (15.1)
 41–50 years321 (36.9)178 (39.6)
 51–60 years221 (25.4)109 (24.2)
 ≥61 years132 (15.2)44 (9.8)
Hospital stay
 1–10 days350 (40.2)213 (47.3)6.8520.079
 11–20 days273 (31.3)133 (29.6)
 21–30 days131 (15.1)74 (16.4)
 ≥30 days117 (13.4)30 (6.7)
Marriage status
 Married795 (91.3)427 (94.9)5.1180.037
 Unmarried76 (8.7)23 (5.1)
Surgical treatments
 Yes717 (82.3)339 (75.3)1.7210.203
 No154 (17.7)111 (24.7)
Therapeutic options
 Surgery144 (16.5)106 (23.6)11.9750.029
 Surgery in combine with chemotherapy or radiotherapy395 (45.4)189 (42)
 Surgery in combine with chemotherapy and radiotherapy122 (14)46 (10.2)
 Chemotherapy or radiotherapy113 (13)54 (12)
 Chemotherapy and radiotherapy54 (6.2)26 (5.8)
 Others43 (4.9)29 (6.4)
Pathological type
 Squamous cell carcinoma707 (81.2)370 (82.2)4.0140.249
 Adenocarcinoma109 (12.5)53 (11.8)
 Adenosquamous carcinoma37 (4.2)17 (3.8)
 Others18 (2.1)10 (2.2)
Lymphatic metastasis
 Yes448 (51.4)264 (58.7)2.5130.121
 No423 (48.6)186 (41.3)
Distant metastasis and recurrence
 Yes285 (32.7)169 (37.6)0.1010.746
 No586 (67.3)281 (62.4)
Basic information of medical insured and uninsured patients (n (%))

Inpatient medical expenditure of insured and uninsured patients

In the study, the inpatient medical expenditures of medical insured and uninsured patients were RMB 29,509.1 Yuan and RMB 22,114.3 Yuan, respectively. Of the specifics, drug costs, surgery costs as well as treatment costs were the top three cost categories, with drug costs accounted for 37.7% and 33.8% of the total costs, surgery costs accounted for accounted for 21.5% and 25.5%, treatment costs accounted for 18.7% and 16.4%, whereas the costs of imaging and laboratory examinations accounted for 16.4% and 15.2% among insured and uninsured patients, respectively, as shown in Table 3.
Table 3

Hospitalization expenses and constitutions of medical insured and uninsured patients

Cost itemsInsured patientsUninsured patients


Median value (RMB Yuan)Proportion (%)Median value (RMB Yuan)Proportion (%)
Treatment costs5518.118.73626.716.4
Drug costs9649.532.76811.230.8
Imaging and laboratory examination costs4839.516.43361.415.2
Surgery costs6344.521.55639.125.5
Other costs324.61.1398.11.8
Bed charges1298.44.4906.74.1
Nursing costs1534.55.21371.16.2

Total costs29,509.110022,114.3100
Hospitalization expenses and constitutions of medical insured and uninsured patients

Influence of payment modes toward inpatient medical expenditures of cervical cancer patients

The results of Gamma analysis between different payment modes toward the inpatient medical expenditures of cervical cancer were shown in Table 4; as payment modes, therapeutic options as well as the recurrence and metastasis of tumor were counted as statistically significant. Further analyses on medical costs of the insured and uninsured inpatient costs as we regulated the covariates were shown in Table 5, while total costs, drug costs, treatment costs as well as examination costs were significantly different between medical insured and uninsured patients, as the total hospitalization costs, drug costs, treatment costs, and examination costs of insured inpatient were 1.33, 1.42, 1.52, and 1.44 times of uninsured patients, respectively.
Table 4

Multivariate analysis of the influencing factors of hospitalization expenses in cervical cancer patients using Gamma model

Variablesχ2P
Age0.5010.793
Marriage status2.8230.402
Payment modes8.7190.029
Therapeutic options89.725<0.001
Surgical treatments0.2510.596
Pathological types5.1070.163
Lymphatic metastasis0.8970.314
Distant metastasis and recurrence12.998<0.001
Table 5

The results of Gamma analysis on different cost items of medical insured and uninsured patients

VariablesPayment modesMarginal mean value (RMB Yuan)χ2P
Treatment costsInsured9380.312.0060.019
Uninsured7514.9
Average deviation1865.40.027
Drug costsInsured4545.04.8320.031
Uninsured3925.1
Average deviation619.90.042
Imaging and laboratory examinations costsInsured8275.59.1070.028
Uninsured7047.6
Average deviation1227.90.015
Surgery costsInsured8247.95.2840.113
Uninsured8118.4
Average deviation129.50.102
Other costsInsured451.22.2150.136
Uninsured402.3
Average deviation48.90.164
Bed chargesInsured1752.85.7910.119
Uninsured1500.8
Average deviation252.00.104
Nursing costsInsured2148.32.8970.139
Uninsured2002.8
Average deviation145.50.145

Total costsInsured20,656.49.1980.003
Uninsured17,980.0
Average deviation2676.140.006
Multivariate analysis of the influencing factors of hospitalization expenses in cervical cancer patients using Gamma model The results of Gamma analysis on different cost items of medical insured and uninsured patients

DISCUSSION

Influence of payment modes toward total inpatient medical expenditures among cervical cancer patients

As is widely known, payment modes have significant influence toward medical expenditures in clinical. According to the study, marital status and treatment options were statistically significant in inpatient medical expenditures between medical insured patient and uninsured patients.[12] Notably, marital status is somehow related to the medical insurance type among some patients and that medical insurance status may influence patients' choices on treatment options.[13] Thus, to exclude the influence of covariates, Gamma model was adopted to control the other covariates in further analyses, and results showed that the hospitalization expenses among cervical cancer patients with medical insurance were significantly higher than those without, this is in accordance with other domestic and foreign researches.[14] Here are several possible reasons: first, the proportion of uninsured patients in China is still quite large since the medical insurance coverage is not complete, which may place limits to their medical behavior in a certain degree when seeking medical treatments.[15] Second, according to relevant studies, different medical payment modes are having certain stimulations and inducements toward doctors in their therapeutic behaviors. This may largely attribute to the self-financing reality of Chinese hospitals since health-care funds in China are seriously insufficient, and that some medical service providers are inclined to provide excessive treatments due to economic-induced demands since it is directly related to the profit of the hospitals and the income of medical staffs.[16] Last but not least, the diagnosis of cervical cancer was selected as the trial item in the first diagnosis-related groups' prospective payment system categories in China, which might result to excessive medical services among patients with health-care insurance.[17]

Influence of therapeutic options as well as recurrence and metastasis of tumor toward total inpatient medical expenditures among cervical cancer patients

According to Gamma model analysis, the results of therapeutic options as well as the recurrence and metastasis of tumor toward the inpatient medical expenditures of cervical cancer were statistically significant. In regard to the characteristics of cervical cancer, it was explicable that the medical costs of different therapeutic options vary significantly since a great amount of adjunctive therapies and maintenance therapy (such as chemotherapies, radiotherapy as well as immunotherapies) might be involved in the treatment. While the recurrence and metastasis of tumor reflect the severity of disease, the status of patients, and the difficulty in further treatment, it is obvious that the variance in the indicator has significant differences toward the overall medical costs among cervical cancer patients.

Influence of payment modes toward different medical cost items among cervical cancer patients

In the research, Gamma model was also applied in analyzing the average medical expenses toward different cost items in the control of other covariates. Moreover, results showed that drug costs, treatment costs, and examination costs of medical insured patients are 1.42, 1.52, and 1.44 times of uninsured patients. On the contrary, since other costs items (such as surgery costs, bed charges as well as nursing costs) are nonnegligible and irreplaceable for the treatment, no significant difference between medical insured and uninsured patients was shown in the study. Furthermore, it is believed that the differences in drug costs will gradually be narrowed between medical insured and uninsured patients, and the gaps of other cost items will be relatively expanded with the implementation of health-care reform policies when the profits of drug makeups were cancelled, and the usage of unnecessary drugs was further cut down by the hospital.[18]

Application of Gamma model in medical cost analysis

The statistical methods that most frequently used in medical cost analysis including multiple linear models, logistic regression as well as various multivariate statistical analyses.[19] As for the cost analyses of nonnormal distributions, the most commonly used method is the construction of the multiple linear model by the logarithm transformation of the original data. However, the application of the method calls for strict conditions, and the intercept estimation bias may exist in the predictive values of exponentiation cost estimations.[20] Logistic regression does not require normal distribution and homogeneity of variance, but the integrity of data information was reduced through the classification of the continuous cost data.[21] In comparison, the Gamma model processes the data with the log linked gamma distribution with regard to the skewed distribution characteristics of the cost data, ensures the integrity of the original data information, and avoids the conversion bias.[22] The results of similar studies show that the Gamma model is more suitable for a medical cost analysis by comparing the results of multiple linear regressions and the logarithmic link Gamma model since the estimated average cost values through Gamma model are closer to the actual value.[23] Thus, the analysis of medical expenditures based on Gamma model could be applied to other similar single diseases such as uterine benign diseases, normal deliveries, and other common diagnoses of gynecology. Since the study was based on a single-centered hospital, considering the differences in economic level, medical insurance policies as well as epidemiology of the disease, the generalization of the results should be more careful in other regions and circumstances.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.
  22 in total

1.  Malignant epignathus including a nephroblastoma component and successful management.

Authors:  E Zeynep Ince; Ferhat Cekmez; Şükran Yıldırım; Atalay Demirel; Bilge Bilgic; Isın Kılıcaslan; Asuman Coban
Journal:  Ann Diagn Pathol       Date:  2012-03-08       Impact factor: 2.090

2.  Effect of visual screening on cervical cancer incidence and mortality in Tamil Nadu, India: a cluster-randomised trial.

Authors:  Rengaswamy Sankaranarayanan; Pulikkottil Okkuru Esmy; Rajamanickam Rajkumar; Richard Muwonge; Rajaraman Swaminathan; Sivanandam Shanthakumari; Jean-Marie Fayette; Jacob Cherian
Journal:  Lancet       Date:  2007-08-04       Impact factor: 79.321

3.  The role of conceptual frameworks in epidemiological analysis: a hierarchical approach.

Authors:  C G Victora; S R Huttly; S C Fuchs; M T Olinto
Journal:  Int J Epidemiol       Date:  1997-02       Impact factor: 7.196

Review 4.  Human papillomavirus infection and the multistage carcinogenesis of cervical cancer.

Authors:  Mark Schiffman; Nicolas Wentzensen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-04       Impact factor: 4.254

5.  Incidence of endometriosis by study population and diagnostic method: the ENDO study.

Authors:  Germaine M Buck Louis; Mary L Hediger; C Matthew Peterson; Mary Croughan; Rajeshwari Sundaram; Joseph Stanford; Zhen Chen; Victor Y Fujimoto; Michael W Varner; Ann Trumble; Linda C Giudice
Journal:  Fertil Steril       Date:  2011-06-29       Impact factor: 7.329

6.  Knowledge, attitude and practice of cervical cancer screening in women visiting a tertiary care hospital of Delhi.

Authors:  M Singh; R Ranjan; B Das; K Gupta
Journal:  Indian J Cancer       Date:  2014 July-September       Impact factor: 1.224

Review 7.  Clinical diagnosis of pelvic endometriosis: a scoping review.

Authors:  Hedyeh Riazi; Najmeh Tehranian; Saeideh Ziaei; Easa Mohammadi; Ebrahim Hajizadeh; Ali Montazeri
Journal:  BMC Womens Health       Date:  2015-05-08       Impact factor: 2.809

Review 8.  Evolving Molecular Genetics of Glioblastoma.

Authors:  Qiu-Ju Li; Jin-Quan Cai; Cheng-Yin Liu
Journal:  Chin Med J (Engl)       Date:  2016-02-20       Impact factor: 2.628

Review 9.  Role of MicroRNAs in Malignant Glioma.

Authors:  Bao-Cheng Wang; Jie Ma
Journal:  Chin Med J (Engl)       Date:  2015-05-05       Impact factor: 2.628

10.  Preterm birth: Case definition & guidelines for data collection, analysis, and presentation of immunisation safety data.

Authors:  Julie-Anne Quinn; Flor M Munoz; Bernard Gonik; Lourdes Frau; Clare Cutland; Tamala Mallett-Moore; Aimee Kissou; Frederick Wittke; Manoj Das; Tony Nunes; Savia Pye; Wendy Watson; Ana-Maria Alguacil Ramos; Jose F Cordero; Wan-Ting Huang; Sonali Kochhar; Jim Buttery
Journal:  Vaccine       Date:  2016-10-13       Impact factor: 3.641

View more
  2 in total

1.  The Lifetime Cost Estimation of Human Papillomavirus-related Diseases in China: A Modeling Study.

Authors:  Wenpei Ding; Yue Ma; Chao Ma; Daniel C Malone; Aixia Ma; Wenxi Tang; Lei Si
Journal:  J Transl Int Med       Date:  2021-09-28

2.  Study of Hospitalization Costs in Patients with Cerebral Ischemia Based on E-CHAID Algorithm.

Authors:  Jing Gong; Ying Wang; Siou-Tang Huang; Herng-Chia Chiu
Journal:  J Healthc Eng       Date:  2022-05-02       Impact factor: 3.822

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.